Tranylcypromine Sulfate NDC 0591-5590

NDC codes

FDA NDC Directory

Product NDC (as listed)0591-5590Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00591-5590Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0591-5590-01	00591559001	100 TABLET, FILM COATED in 1 BOTTLE (0591-5590-01)Marketed from Feb 5, 2016

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Tranylcypromine Sulfate
Generic name (nonproprietary): tranylcypromine sulfate
Active ingredients: Tranylcypromine sulfate — 10 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Actavis Pharma, Inc.
Product type: Prescription drug
Marketing category: NDA authorized genericApplication NDA 012342
Marketing start: Feb 5, 2016
Listing expires: Dec 31, 2026
Other FDA classes: Monoamine Oxidase Inhibitors (Mechanism)
Identifiers: Product ID 0591-5590_e42c8b23-863e-4370-a3b1-b71526b12ee5SPL ID e42c8b23-863e-4370-a3b1-b71526b12ee5SPL set ID 6a0b609b-0625-4c26-91a1-59ee3ece3ddfRxCUI 313447UNII 7ZAT6ES870
Pharmacologic class: Monoamine Oxidase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400591559001 followed by a unit qualifier and the quantity

Package 00591-5590-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 25, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Tranylcypromine sulfate tablets are indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants. Tranylcypromine sulfate tablets are not indicated for the initial treatment of MDD due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions [see Contraindications (4), Warnings and Precautions (5) , and Drug Interactions (7)]. Tranylcypromine sulfate tablets are a monoamine oxidase inhibitor (MAOI) indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants ( 1 ) Tranylcypromine sulfat…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 012342

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 012342
Product	Strength	Form · route	Labeler	Product NDC
Parnatetranylcypromine sulfate	Tranylcypromine sulfate 10 mg/1	Tablet, Film coatedOral	Advanz Pharma (US) Corp.	59212-447